Bli medlem
Bli medlem

Du är här


DBV Technologies: DBV Technologies to Present at the LEERINK Partners 6th Annual Global Healthcare Conference

| Press Release |
| |
|Montrouge, France, January 26, 2017 |

DBV Technologies to Present at the LEERINK Partners 6th Annual Global Healthcare ConferenceDBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market:
DBVT), today announced that Susanna Mesa, Senior Vice President, Strategy,
will present at the LEERINK Partners 6th Annual Global Healthcare Conference
on Wednesday, February 15, 2017, at 3:30 pm EST at the Lotte New York Palace
Hotel in New York.

A live webcast of the presentation will be available on the Investor Relations
section of the Company's
website, A replay will
also be available 48 hours after the event.

About DBV Technologies

DBV Technologies is developing Viaskin®, a proprietary technology platform
with broad potential applications in immunotherapy. Viaskin is based on
epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically
active compounds to the immune system through intact skin. With this new
class of self-administered and non-invasive product candidates, the company
is dedicated to safely transforming the care of food allergic patients, for
whom there are no approved treatments. DBV's food allergies programs include
ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical
development of Viaskin Egg. DBV is also pursuing a human proof-of-concept
clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis,
and exploring potential applications of its platform in vaccines and other
immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York,
NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV,
ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq
Global Select Market in the form of American Depositary Shares (each
representing one-half of one ordinary share) (Ticker: DBVT). For more
information on DBV Technologies, please visit our

Forward Looking Statements

This press release contains forward-looking statements, including statements
reflecting management's expectations regarding the clinical development of
Viaskin Peanut, the safety, efficacy and durability of Viaskin Peanut for the
treatment of peanut allergy, and the commercial potential of Viaskin Peanut.
These forward-looking statements are not promises or guarantees and involve
substantial risks and uncertainties. Among the factors that could cause
actual results to differ materially from those described or projected herein
include uncertainties associated generally with research and development,
clinical trials and related regulatory reviews and approvals, the risk that
historical clinical trial results may not be predictive of future trial
results and the risk that Viaskin Peanut may not receive regulatory approval
notwithstanding the results of clinical trials. A further list and
description of these risks, uncertainties and other risks can be found in the
Company's regulatory filings with the French Autorité des Marchés Financiers,
the Company's Securities and Exchange Commission filings and reports,
including in the Company's Annual Report on Form 20-F for the year ended
December 31, 2015 and future filings and reports by the Company. Existing and
prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. DBV
Technologies undertakes no obligation to update or revise the information
contained in this Press Release, whether as a result of new information,
future events or circumstances or otherwise.

DBV Technologies Contact

Susanna Mesa

Senior Vice President, Strategy
+1 212-271-0861

Media Contact Europe

Caroline Carmagnol, Alize RP, Relations Presse

+33 (0)6 64 18 99 59

PDF Version

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: DBV Technologies via Globenewswire

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.